|
業務類別
|
Biotechnology |
|
業務概覽
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States. |
| 公司地址
| 730 Third Avenue, 9th Floor, New York, NY, USA, 10017 |
| 電話號碼
| +1 781 419-1400 |
| 傳真號碼
| +1 781 419-1420 |
| 公司網頁
| https://www.syndax.com |
| 員工數量
| 277 |
| Mr. Luke J. Albrecht |
General Counsel and Secretary |
美元 471.00K |
01/04/2025 |
| Dr. Neil Gallagher, M.D. |
President and Head of Research and Development |
美元 546.00K |
16/05/2025 |
| Mr. Keith A. Goldan |
Chief Financial Officer and Principal Accounting Officer |
美元 497.00K |
26/02/2026 |
| Mr. Michael A. Metzger |
Director and Chief Executive Officer |
美元 715.00K |
26/02/2026 |
| Mr. Steven Closter |
Chief Commercial Officer |
美元 364.17K |
01/04/2025 |
| Dr. Nicholas A.J. Botwood |
Head, Research and Development and Chief Medical Officer |
-- |
16/05/2025 |
|
|
| Dr. Aleksandra Rizo, M.D.,PhD |
Independent Director |
26/02/2026 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
26/02/2026 |
| Dr. Martin H. Huber, M.D. |
Independent Director |
26/02/2026 |
| Mr. Michael A. Metzger |
Director and Chief Executive Officer |
26/02/2026 |
| Mr. Pierre Legault, C.P.A.,M.B.A. |
Independent Director |
26/02/2026 |
| Mr. Keith A. Katkin |
Independent Director |
26/02/2026 |
| Mr. Dennis G. Podlesak |
Chairman of the Board |
26/02/2026 |
|
|
|
|
